Amid a swell of regulatory successes in the myasthenia gravis arena this decade, Amgen is wading into the fray with a new ...
Zacks Investment Research on MSN
JNJ vs. PFE: Which blue-chip drug stock is the better investment now?
Johnson & Johnson JNJ and Pfizer PFE are both healthcare leaders with large drug portfolios and diversified revenue streams, ...
Johnson & Johnson has received European Commission approval for nipocalimab, marketed as IMAAVY, as an add-on therapy for ...
Beerse: Johnson & Johnson has announced that the European Commission has approved a Marketing Authorisation for IMAAVY ...
Johnson & Johnson's Imaavy has become the first FcRn blocker to be approved in the EU as a treatment for both adolescent and ...
Nipocalimab is the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK antibody-positive In the pivotal Phase 3 Vivacity-MG3 and ...
Nipocalimab shows promise in treating myasthenia gravis in children, with ongoing trials revealing safety and efficacy similar to adult studies, says Jonathan Strober, MD. The VIBRANCE-MG trial ...
Results from the phase III VIBRANCE-MG study presented at the American Association of Neuromuscular & Electrodiagnostic Medicine annual meeting showed that nipocalimab (Imaavy) was safe and ...
Nipocalimab, a first-in-class FcRn blocker being investigated for SjD, met its primary endpoint in the Phase 2 DAHLIAS study with statistically significant improvement in ClinESSDAI score, which is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback